← All trials
NCT06384638
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Jan 16, 2024
- Completion date
- Feb 9, 2024
- First posted
- Apr 25, 2024
- Last posted
- Apr 25, 2024
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Misr University for Science and TechnologyLead sponsor
- Misr University for Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.